Clare Foss, MD
Dermatology · Richmond, VANPI 1306080932
Payments from drug & device makers
Across 67 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$234
- AbbVie$178
- Lilly USA, LLC$155
- Johnson & Johnson$129
- Regeneron Healthcare Solutions, Inc.$108
- UCB, Inc.$98
- plus $621 from 16 others
What the payments were for
- Food & beverage$1,523100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 10 | $234 |
| AbbVie | 8 | $178 |
| Lilly USA, LLC | 6 | $155 |
| Johnson & Johnson(2 entities) | 5 | $129 |
| Regeneron Healthcare Solutions, Inc. | 4 | $108 |
| UCB, Inc. | 4 | $98 |
| Novartis | 3 | $74 |
| Galderma Laboratories, L.p. | 2 | $66 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $65 |
| Sun Pharmaceutical Industries Inc. | 2 | $63 |
| LEO Pharma Inc. | 4 | $58 |
| Amgen | 3 | $57 |
| Sanofi | 2 | $44 |
| Pfizer | 2 | $32 |
| VYNE Pharmaceuticals Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Almirall LLC | 1 | $20 |
| Arcutis Biotherapeutics, Inc. | 1 | $19 |
| Biofrontera Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Bristol Myers Squibb | 1 | $18 |
How this compares
$1,523 in reported general payments places this provider in the 45th percentile of 396 dermatology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 21 | $95,819 |
| Dupixent PenDupilumab | 12 | $42,695 |
| Fluorouracil | 25 | $1,696 |
| Ketoconazole | 27 | $517 |
| Clobetasol Propionate | 19 | $496 |
| Triamcinolone Acetonide | 48 | $309 |
| ValacyclovirValacyclovir Hcl | 23 | $289 |
| Mupirocin | 31 | $191 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Richmond
- Yvonne KnightRichmond$857K
- Mohammed DanyRichmond$74K
- Suzanne PeckRichmond$51K
- Melissa KingRichmond$15K
- Victoria GrossRichmond$14K
- Margaret TerhuneRichmond$13K
- David PariserNorfolk$7M
- Jennifer DesimoneFairfax$2.3M
- Naiem IssaVienna$2M
- Saurabh SinghFairfax$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.